For Immediate Release

Frontier Scientific Inc. acquires Echelon Biosciences Inc.

Salt Lake City, Utah, December 3, 2007 – Frontier Scientific Inc, a Logan, Utah, based discovery biochemistry company providing reagents and fine chemicals for research and drug discovery has acquired Echelon Biosciences Inc., a Salt Lake City based biotechnology company, from Aeterna Zentaris Inc. (Nasdaq: AEZS).

Both companies will benefit from this new relationship. Frontier has a proven track-record of specialized biochemical synthetic organic chemistry with experience in drug development, small molecule building blocks, and material science. Its unique light-activitated chemistries have broad industrial and medical applications. One of Frontier’s molecules is approved for certain cancer tumor treatment in Japan and is in late stage human studies in the US. Echelon has a successful history and is a world-recognized expert in the development and marketing of critical reagents and assays to look inside the human cell at lipids-related signaling mistakes that lead to diseases like cancer, diabetes, and inflammation. It previously has moved small molecules into successful early animal studies targeting ovarian cancer. Both companies have promising activities in the field of new potential antibacterials.

Dr. Jerry Bommer, President of Frontier Scientific commented, “Frontier Scientific and Echelon Biosciences both have outstanding personnel and complementary markets, technologies, facilities, and operations. The acquisition will lead to new technology development and growth opportunities. We are excited to blend our scientific teams and expand both companies activities in cell biology, disease detection, and potential new drug development.”

W. Tim Miller, President and CEO of Echelon Biosciences stated, “We are excited about the combination on a number of fronts including exciting scientific synergy between the two companies, blending two outstanding teams of employees, a strengthened biotechnology base for the State of Utah, and the opportunity to merge two critically important biological platforms for improved diagnostics and therapeutics. Our common human biology focus and unique but complementary scientific skill sets will allow us to leverage significantly each others’ efforts.”

The companies address a common life sciences research customer base which includes major pharmaceutical companies and research universities around the world. The companies will maintain their current facilities in Logan and Salt Lake City and begin to work toward a common senior management structure.

About Frontier Scientific, Inc.
Frontier Scientific Inc. (FSI) is a chemical developer, manufacturer and custom research services provider to the pharmaceutical, biotechnology, industrial chemical, government, and academic sectors. FSI specializes in the development of chemical compounds and processes related to porphyrins, phthalocyanines and boronic acids. FSI is a privately held corporation established in 1975 and headquartered in Logan, Utah.

About Echelon Biosciences Inc.
Echelon Biosciences Inc. is engaged in furthering the science of lipid cell signalling and critical metabolic enzymes, which provide new and viable targets for the development of potential drugs and diagnostics for cancer, diabetes, inflammation, infections, and cardiovascular disease. Echelon’s novel assays are used by scientists around the world to identify enzyme inhibitors and signaling antagonists in the search for a new generation of pharmaceuticals. Echelon is an innovative rapidly growing company that is committed to accelerating drug discovery and bringing life saving therapeutics to market.